Shares of SkinBioTherapeutics plc (LON:SBTX – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as GBX 5 and last traded at GBX 5.57, with a volume of 9,293 shares. The stock had previously closed at GBX 5.50.
SkinBioTherapeutics Stock Up 1.0%
The firm has a market capitalization of £13.74 million, a PE ratio of -33.12 and a beta of 0.10. The company has a quick ratio of 10.01, a current ratio of 6.14 and a debt-to-equity ratio of 11.77. The company’s fifty day simple moving average is GBX 7.27 and its 200 day simple moving average is GBX 10.33.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Read More
- Five stocks we like better than SkinBioTherapeutics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
